Aurinia Reports Third Quarter 2017 Financial Results and Provides Operational Highlights

16:00 EST 14 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
AURORA Phase III Trial in lupus nephritis on track Trials in FSGS, MCD and Dry Eye to begin in the first half of 2018 Cash of $182.4 million as of September 30, 2017 Aurinia Pharmaceuticals Inc. (NASDAQ:AUP...

Other Sources for this Article

Aurinia Pharmaceuticals Inc.
Investors & Media:
Celia Economides
Head of IR & Communications
Chief Financial Officer:
Dennis Bourgeault


More From BioPortfolio on "Aurinia Reports Third Quarter 2017 Financial Results and Provides Operational Highlights"

Quick Search


Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...